secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055647
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago
------------------------------------------------------------------------

- NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)
- Net income of $16.6M ($0.10 EPS) compared to net loss of $43.0M ($0.27 loss) in Q1 2023
- Full-year 2024 guidance reiterated: DAYBUE $370-420M, NUPLAZID $560-590M
- Cash and investments $470.5M at quarter end, up from $438.9M at Dec 31 2023
- Appointed Elizabeth H.Z. Thompson as EVP, Head of R&D

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/0000950170-24-055647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017024055647/acad-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer